Mirum Pharmaceuticals, Inc. (MIRM) Operating Margin
- Operating margin · 12 months: Value -134.93%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -134.93% | Operating income / revenue. Period ending 2026-06-30. $-833.97M ÷ $618.07M × 100 ≈ -134.93% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -833.97M USD | Operating Income (Loss) |
| Revenue | 618.07M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 313.84M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-833.97M | $618.07M | (m) | (m) | $313.84M | -134.93% |
| 2026-03-31 | $-796.42M | $569.61M | (m) | (m) | $295.65M | -139.82% |
| 2025-12-31 | $-22.14M | $521.31M | (m) | (m) | $257.03M | -4.25% |
| 2025-09-30 | $-41.79M | $471.79M | (m) | (m) | $239.73M | -8.86% |
| 2025-06-30 | $-57.08M | $429.16M | (m) | (m) | $228.37M | -13.30% |
| 2025-03-31 | $-76.32M | $379.25M | (m) | (m) | $214.29M | -20.12% |
| 2024-12-31 | $-87.61M | $336.89M | (m) | (m) | $202.22M | -26.00% |
| 2024-09-30 | $-95.97M | $307.03M | (m) | (m) | $191.57M | -31.26% |
| 2024-06-30 | $-108.43M | $264.38M | (m) | (m) | $177.56M | -41.01% |
| 2024-03-31 | $-108.47M | $224.00M | (m) | (m) | $161.30M | -48.43% |
| 2023-12-31 | $-109.15M | $186.37M | (m) | (m) | $145.88M | -58.57% |
| 2023-09-30 | $-110.73M | $144.73M | (m) | (m) | $126.16M | -76.51% |
| 2023-06-30 | $-118.46M | $115.78M | (m) | (m) | $112.15M | -102.32% |
| 2023-03-31 | $-125.63M | $95.77M | (m) | (m) | $100.17M | -131.18% |
| 2022-12-31 | $-131.22M | $77.06M | (m) | (m) | $89.07M | -170.28% |
| 2022-09-30 | $-142.63M | $52.29M | (m) | (m) | (m) | -272.75% |
| 2022-06-30 | $-152.58M | $38.51M | (m) | (m) | (m) | -396.16% |
| 2022-03-31 | $-158.54M | $32.03M | (m) | (m) | (m) | -494.96% |
| 2021-12-31 | $-173.41M | $19.14M | (m) | (m) | (m) | -906.12% |
| 2021-09-30 | $-164.79M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-143.68M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-129.88M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-104.30M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-86.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-80.15M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-70.59M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-54.74M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |